FIBROGEN INC - COMMON

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

13 11 2024 15:58:52 提供 NetDania Notify

FibroGen Reports Third Quarter 2024 Financial Results

12 11 2024 16:05:02 提供 Nasdaq GlobeNewswire

FibroGen to Report Third Quarter 2024 Financial Results

04 11 2024 16:05:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

31 10 2024 16:00:39 提供 NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

28 10 2024 10:16:28 提供 NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

09 10 2024 10:58:40 提供 NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

08 10 2024 09:46:54 提供 NetDania Notify

FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03 9 2024 16:05:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

03 9 2024 12:45:29 提供 NetDania Notify

FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update

06 8 2024 16:05:02 提供 Nasdaq GlobeNewswire

FibroGen to Report Second Quarter 2024 Financial Results

30 7 2024 16:07:00 提供 Nasdaq GlobeNewswire

FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update

30 7 2024 16:05:00 提供 Nasdaq GlobeNewswire

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

18 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

03 6 2024 16:05:00 提供 Nasdaq GlobeNewswire

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

03 6 2024 16:02:00 提供 Nasdaq GlobeNewswire

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting

23 5 2024 17:05:00 提供 Nasdaq GlobeNewswire

FibroGen to Participate in Upcoming Investor Conferences

07 5 2024 07:00:01 提供 Nasdaq GlobeNewswire

FibroGen Reports First Quarter 2024 Financial Results

06 5 2024 16:02:00 提供 Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2024 Financial Results

29 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

24 4 2024 16:02:00 提供 Nasdaq GlobeNewswire